Myesha Lacy is Adverum’s vice president of investor relations and corporate communications and joined the Company in August 2019. Ms. Lacy has 25 years of experience as a communicator, providing strategy, development, and execution of communications programs, both internally and externally, for publicly traded pharmaceutical and biotechnology companies. Prior to joining Adverum, she was vice president, investor relations and corporate communications at Global Blood Therapeutics, Inc., a $3 billion market capitalization company. Previously, she led this function at ZS Pharma, Inc. (acquired by AstraZeneca PLC), Hyperion Therapeutics, Inc. (acquired by Horizon Pharma), and other publicly-traded biotechnology companies. Ms. Lacy earned a B.A. in Business from Holy Names University.